# Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)

> **NCT02038946** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 116 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02038946
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-26
- **Primary completion:** 2017-05-17
- **Final completion:** 2020-12-28
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2022-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02038946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02038946, "Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02038946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*